期刊文献+

非酒精性脂肪性肝病发病机制的研究进展 被引量:17

Advances in pathogenesis of non-alcoholic fatty liver disease
在线阅读 下载PDF
导出
摘要 非酒精性脂肪性肝病(NAFLD)是指与过量饮酒无关的临床综合征,主要病理改变包括肝细胞弥漫性脂肪变性和脂肪堆积。NAFLD动物模型表现出显著的肝脏微循环障碍,关于其形成机制,被广为接受的为"二次打击"学说。该学说认为肥胖、胰岛素抵抗等因素作为"第一次打击",导致肝脏中脂质堆积,形成单纯性脂肪肝,增加了"第二次打击"造成的肝脏损伤的易感性,这些因素包括炎症、枯否细胞功能障碍、氧化应激、线粒体障碍、脂肪因子调节紊乱等,导致非酒精性脂肪性肝炎甚至纤维化等更严重疾病的发生。 Non-alcoholic fatty liver disease(NAFLD),a clinical syndrome unrelated to excessive alcohol intake,is char-acterized by diffuse fatty degeneration of liver cells and fat accumulation.Animal models of NAFLD exhibit obvious hepatic mi-crocirculation dysfunction.The widely accepted pathogenesis of NAFLD was based on ′2-hit hypothesis′.Obesity and insulin re-sistance as the ′first-hit′ lead to hepatic triglyceride accumulation or steatosis,increase susceptibility of the liver to injury me-diated by ′second-hit′,such as inflammation,Kupffer cell dysfunction,mitochondrial dysfunction,oxidative stress,and adipokines adjustment disorders,which in turn lead to steatohepatitis,even fibrosis.
作者 李娟 叶菲
出处 《国际药学研究杂志》 CAS 2011年第5期341-344,共4页 Journal of International Pharmaceutical Research
基金 科技部"重大新药创制"科技重大专项"十一五"计划(2009ZX09103-432 2009ZX09303-003)
关键词 非酒精性脂肪性肝病 微循环 流行病学 实验动物模型 发病机制 non-alcoholic fatty liver disease(NAFLD) microcirculation epidemiology experimental animal mod-els pathogenesis
  • 相关文献

参考文献8

  • 1Baffy G.Kupffer cells in non-alcoholic fatty liver disease:the emerging view[J].J Hepatol,2009,51 (1):212-223.
  • 2Kirovski G,Schacherer D,Wobser H,et al.Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric,biochemical and sonographic characteristics[J].Int J Clin Exp Med,2010,3(3):202-210.
  • 3Bedogni G,Miglioli L,Masutti F,et al.Prevalence of and risk factors for nonalcoholic fatty liver disease:the Dionysos nutrition and liver study[J].Hepatology,2005,42(1):44-52.
  • 4Browning JD,Szczepaniak LS,Dobbins R,et al.Prevalence of hepatic steatosis in an urban population in the United States:impact of ethnicity[J].Hepatology,2004,40(6):1387-1395.
  • 5Dowman JK,Tomlinson JW,Newsome PN.Pathogenesis of non-alcoholic fatty liver disease[J].QJM,2009,103 (2):71-83.
  • 6Maher JJ,Leon P,Ryan JC.Beyond insulin resistance:innate immunity in nonalcoholic steatohepatitis[J].Hepatology,2008,48(2):670-678.
  • 7Yu-Tao Zhan,Wei An.Roles of liver innate immune cells in nonalcoholic fatty liver disease[J].World Journal of Gastroenterology,2010,16(37):4652-4660. 被引量:35
  • 8R Scott Rector,John P Thyfault,Yongzhong Wei,Jamal A Ibdah.Non-alcoholic fatty liver disease and the metabolic syndrome:An update[J].World Journal of Gastroenterology,2008,14(2):185-192. 被引量:60

二级参考文献92

  • 1[37]Gholam PM,Flancbaum L,Machan JT,Charney DA,Kotler DP.Nonalcoholic fatty liver disease in severely obese subjects.Am J Gastroenterol 2007; 102:399-408
  • 2[38]Hui JM,Kench JG,Chitturi S,Sud A,Farrell GC,Byth K,Hall P,Khan M,George J.Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.Hepatology 2003; 38:420-427
  • 3[39]Angelico F,Del Ben M,Conti R,Francioso S,Feole K,Fiorello S,Cavallo MG,Zalunardo B,Lirussi F,Alessandri C,Violi F.Insulin resistance,the metabolic syndrome,and nonalcoholic fatty liver disease.J Clin Endocrinol Metab 2005; 90:1578-1582
  • 4[40]Liangpunsakul S,Chalasani N.Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome:results from the third National Health and Nutrition Survey (NHANES Ⅲ).Am J Med Sci 2005; 329:111-116
  • 5[41]Nilssen O,Forde OH,Brenn T.The Tromso Study.Distribution and population determinants of gamma-glutamyltransferase.Am J Epidemiol 1990; 132:318-326
  • 6[42]Robinson D,Whitehead TP.Effect of body mass and other factors on serum liver enzyme levels in men attending for well population screening.Ann Clin Biochem 1989; 26:393-400
  • 7[43]Wannamethee G,Ebrahim S,Shaper AG.Gamma-glutamyltransferase:determinants and association with mortality from ischemic heart disease and all causes.Am J Epidemiol 1995; 142:699-708
  • 8[44]Perry IJ,Wannamethee SG,Shaper AG.Prospective study of serum gamma-glutamyltransferase and risk of NIDDM.Diabetes Care 1998; 21:732-737
  • 9[45]Yamada J,Tomiyama H,Yambe M,Koji Y,Motobe K,Shüna K,Yamamoto Y,Yamashina A.Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome.Atherosclerosis 2006; 189:198-205
  • 10[46]Stranges S,Trevisan M,Dorn JM,Dmochowski J,Donahue RP.Body fat distribution,liver enzymes,and risk of hypertension:evidence from the Western New York Study.Hypertension 2005; 46:1186-1193

共引文献93

同被引文献215

引证文献17

二级引证文献125

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部